1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Hepatic Encephalopathy Treatment Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Hepatic Encephalopathy Treatment by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Hepatic Encephalopathy Treatment by Country/Region, 2018, 2022 & 2029
2.2 Hepatic Encephalopathy Treatment Segment by Route
2.2.1 Oral
2.2.2 Injectable
2.3 Hepatic Encephalopathy Treatment Sales by Route
2.3.1 Global Hepatic Encephalopathy Treatment Sales Market Share by Route (2018-2023)
2.3.2 Global Hepatic Encephalopathy Treatment Revenue and Market Share by Route (2018-2023)
2.3.3 Global Hepatic Encephalopathy Treatment Sale Price by Route (2018-2023)
2.4 Hepatic Encephalopathy Treatment Segment by Application
2.4.1 Hospital Pharmacy
2.4.2 Retail Pharmacy
2.4.3 Online Pharmacy
2.5 Hepatic Encephalopathy Treatment Sales by Application
2.5.1 Global Hepatic Encephalopathy Treatment Sale Market Share by Application (2018-2023)
2.5.2 Global Hepatic Encephalopathy Treatment Revenue and Market Share by Application (2018-2023)
2.5.3 Global Hepatic Encephalopathy Treatment Sale Price by Application (2018-2023)
3 Global Hepatic Encephalopathy Treatment by Company
3.1 Global Hepatic Encephalopathy Treatment Breakdown Data by Company
3.1.1 Global Hepatic Encephalopathy Treatment Annual Sales by Company (2018-2023)
3.1.2 Global Hepatic Encephalopathy Treatment Sales Market Share by Company (2018-2023)
3.2 Global Hepatic Encephalopathy Treatment Annual Revenue by Company (2018-2023)
3.2.1 Global Hepatic Encephalopathy Treatment Revenue by Company (2018-2023)
3.2.2 Global Hepatic Encephalopathy Treatment Revenue Market Share by Company (2018-2023)
3.3 Global Hepatic Encephalopathy Treatment Sale Price by Company
3.4 Key Manufacturers Hepatic Encephalopathy Treatment Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Hepatic Encephalopathy Treatment Product Location Distribution
3.4.2 Players Hepatic Encephalopathy Treatment Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Hepatic Encephalopathy Treatment by Geographic Region
4.1 World Historic Hepatic Encephalopathy Treatment Market Size by Geographic Region (2018-2023)
4.1.1 Global Hepatic Encephalopathy Treatment Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Hepatic Encephalopathy Treatment Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Hepatic Encephalopathy Treatment Market Size by Country/Region (2018-2023)
4.2.1 Global Hepatic Encephalopathy Treatment Annual Sales by Country/Region (2018-2023)
4.2.2 Global Hepatic Encephalopathy Treatment Annual Revenue by Country/Region (2018-2023)
4.3 Americas Hepatic Encephalopathy Treatment Sales Growth
4.4 APAC Hepatic Encephalopathy Treatment Sales Growth
4.5 Europe Hepatic Encephalopathy Treatment Sales Growth
4.6 Middle East & Africa Hepatic Encephalopathy Treatment Sales Growth
5 Americas
5.1 Americas Hepatic Encephalopathy Treatment Sales by Country
5.1.1 Americas Hepatic Encephalopathy Treatment Sales by Country (2018-2023)
5.1.2 Americas Hepatic Encephalopathy Treatment Revenue by Country (2018-2023)
5.2 Americas Hepatic Encephalopathy Treatment Sales by Route
5.3 Americas Hepatic Encephalopathy Treatment Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Hepatic Encephalopathy Treatment Sales by Region
6.1.1 APAC Hepatic Encephalopathy Treatment Sales by Region (2018-2023)
6.1.2 APAC Hepatic Encephalopathy Treatment Revenue by Region (2018-2023)
6.2 APAC Hepatic Encephalopathy Treatment Sales by Route
6.3 APAC Hepatic Encephalopathy Treatment Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Hepatic Encephalopathy Treatment by Country
7.1.1 Europe Hepatic Encephalopathy Treatment Sales by Country (2018-2023)
7.1.2 Europe Hepatic Encephalopathy Treatment Revenue by Country (2018-2023)
7.2 Europe Hepatic Encephalopathy Treatment Sales by Route
7.3 Europe Hepatic Encephalopathy Treatment Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Hepatic Encephalopathy Treatment by Country
8.1.1 Middle East & Africa Hepatic Encephalopathy Treatment Sales by Country (2018-2023)
8.1.2 Middle East & Africa Hepatic Encephalopathy Treatment Revenue by Country (2018-2023)
8.2 Middle East & Africa Hepatic Encephalopathy Treatment Sales by Route
8.3 Middle East & Africa Hepatic Encephalopathy Treatment Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Hepatic Encephalopathy Treatment
10.3 Manufacturing Process Analysis of Hepatic Encephalopathy Treatment
10.4 Industry Chain Structure of Hepatic Encephalopathy Treatment
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Hepatic Encephalopathy Treatment Distributors
11.3 Hepatic Encephalopathy Treatment Customer
12 World Forecast Review for Hepatic Encephalopathy Treatment by Geographic Region
12.1 Global Hepatic Encephalopathy Treatment Market Size Forecast by Region
12.1.1 Global Hepatic Encephalopathy Treatment Forecast by Region (2024-2029)
12.1.2 Global Hepatic Encephalopathy Treatment Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Hepatic Encephalopathy Treatment Forecast by Route
12.7 Global Hepatic Encephalopathy Treatment Forecast by Application
13 Key Players Analysis
13.1 Mallinckrodt Pharmaceuticals
13.1.1 Mallinckrodt Pharmaceuticals Company Information
13.1.2 Mallinckrodt Pharmaceuticals Hepatic Encephalopathy Treatment Product Portfolios and Specifications
13.1.3 Mallinckrodt Pharmaceuticals Hepatic Encephalopathy Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 Mallinckrodt Pharmaceuticals Main Business Overview
13.1.5 Mallinckrodt Pharmaceuticals Latest Developments
13.2 Salix Pharmaceuticals
13.2.1 Salix Pharmaceuticals Company Information
13.2.2 Salix Pharmaceuticals Hepatic Encephalopathy Treatment Product Portfolios and Specifications
13.2.3 Salix Pharmaceuticals Hepatic Encephalopathy Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 Salix Pharmaceuticals Main Business Overview
13.2.5 Salix Pharmaceuticals Latest Developments
13.3 GlaxoSmithKline plc.
13.3.1 GlaxoSmithKline plc. Company Information
13.3.2 GlaxoSmithKline plc. Hepatic Encephalopathy Treatment Product Portfolios and Specifications
13.3.3 GlaxoSmithKline plc. Hepatic Encephalopathy Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 GlaxoSmithKline plc. Main Business Overview
13.3.5 GlaxoSmithKline plc. Latest Developments
13.4 Pfizer Inc.
13.4.1 Pfizer Inc. Company Information
13.4.2 Pfizer Inc. Hepatic Encephalopathy Treatment Product Portfolios and Specifications
13.4.3 Pfizer Inc. Hepatic Encephalopathy Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Pfizer Inc. Main Business Overview
13.4.5 Pfizer Inc. Latest Developments
13.5 ASKA Pharmaceutical Co., Ltd.
13.5.1 ASKA Pharmaceutical Co., Ltd. Company Information
13.5.2 ASKA Pharmaceutical Co., Ltd. Hepatic Encephalopathy Treatment Product Portfolios and Specifications
13.5.3 ASKA Pharmaceutical Co., Ltd. Hepatic Encephalopathy Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 ASKA Pharmaceutical Co., Ltd. Main Business Overview
13.5.5 ASKA Pharmaceutical Co., Ltd. Latest Developments
13.6 Bausch Health
13.6.1 Bausch Health Company Information
13.6.2 Bausch Health Hepatic Encephalopathy Treatment Product Portfolios and Specifications
13.6.3 Bausch Health Hepatic Encephalopathy Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 Bausch Health Main Business Overview
13.6.5 Bausch Health Latest Developments
13.7 Johnson & Johnson Services, Inc.
13.7.1 Johnson & Johnson Services, Inc. Company Information
13.7.2 Johnson & Johnson Services, Inc. Hepatic Encephalopathy Treatment Product Portfolios and Specifications
13.7.3 Johnson & Johnson Services, Inc. Hepatic Encephalopathy Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 Johnson & Johnson Services, Inc. Main Business Overview
13.7.5 Johnson & Johnson Services, Inc. Latest Developments
13.8 Janssen Global Services
13.8.1 Janssen Global Services Company Information
13.8.2 Janssen Global Services Hepatic Encephalopathy Treatment Product Portfolios and Specifications
13.8.3 Janssen Global Services Hepatic Encephalopathy Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 Janssen Global Services Main Business Overview
13.8.5 Janssen Global Services Latest Developments
13.9 Takeda Pharmaceutical Company Limited
13.9.1 Takeda Pharmaceutical Company Limited Company Information
13.9.2 Takeda Pharmaceutical Company Limited Hepatic Encephalopathy Treatment Product Portfolios and Specifications
13.9.3 Takeda Pharmaceutical Company Limited Hepatic Encephalopathy Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 Takeda Pharmaceutical Company Limited Main Business Overview
13.9.5 Takeda Pharmaceutical Company Limited Latest Developments
13.10 Merck & Co., Inc.
13.10.1 Merck & Co., Inc. Company Information
13.10.2 Merck & Co., Inc. Hepatic Encephalopathy Treatment Product Portfolios and Specifications
13.10.3 Merck & Co., Inc. Hepatic Encephalopathy Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.10.4 Merck & Co., Inc. Main Business Overview
13.10.5 Merck & Co., Inc. Latest Developments
14 Research Findings and Conclusion

List of Tables
Table 1. Hepatic Encephalopathy Treatment Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & ($ millions)
Table 2. Hepatic Encephalopathy Treatment Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & ($ millions)
Table 3. Major Players of Oral
Table 4. Major Players of Injectable
Table 5. Global Hepatic Encephalopathy Treatment Sales by Route (2018-2023) & (K Units)
Table 6. Global Hepatic Encephalopathy Treatment Sales Market Share by Route (2018-2023)
Table 7. Global Hepatic Encephalopathy Treatment Revenue by Route (2018-2023) & ($ million)
Table 8. Global Hepatic Encephalopathy Treatment Revenue Market Share by Route (2018-2023)
Table 9. Global Hepatic Encephalopathy Treatment Sale Price by Route (2018-2023) & (US$/Unit)
Table 10. Global Hepatic Encephalopathy Treatment Sales by Application (2018-2023) & (K Units)
Table 11. Global Hepatic Encephalopathy Treatment Sales Market Share by Application (2018-2023)
Table 12. Global Hepatic Encephalopathy Treatment Revenue by Application (2018-2023)
Table 13. Global Hepatic Encephalopathy Treatment Revenue Market Share by Application (2018-2023)
Table 14. Global Hepatic Encephalopathy Treatment Sale Price by Application (2018-2023) & (US$/Unit)
Table 15. Global Hepatic Encephalopathy Treatment Sales by Company (2018-2023) & (K Units)
Table 16. Global Hepatic Encephalopathy Treatment Sales Market Share by Company (2018-2023)
Table 17. Global Hepatic Encephalopathy Treatment Revenue by Company (2018-2023) ($ Millions)
Table 18. Global Hepatic Encephalopathy Treatment Revenue Market Share by Company (2018-2023)
Table 19. Global Hepatic Encephalopathy Treatment Sale Price by Company (2018-2023) & (US$/Unit)
Table 20. Key Manufacturers Hepatic Encephalopathy Treatment Producing Area Distribution and Sales Area
Table 21. Players Hepatic Encephalopathy Treatment Products Offered
Table 22. Hepatic Encephalopathy Treatment Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
Table 23. New Products and Potential Entrants
Table 24. Mergers & Acquisitions, Expansion
Table 25. Global Hepatic Encephalopathy Treatment Sales by Geographic Region (2018-2023) & (K Units)
Table 26. Global Hepatic Encephalopathy Treatment Sales Market Share Geographic Region (2018-2023)
Table 27. Global Hepatic Encephalopathy Treatment Revenue by Geographic Region (2018-2023) & ($ millions)
Table 28. Global Hepatic Encephalopathy Treatment Revenue Market Share by Geographic Region (2018-2023)
Table 29. Global Hepatic Encephalopathy Treatment Sales by Country/Region (2018-2023) & (K Units)
Table 30. Global Hepatic Encephalopathy Treatment Sales Market Share by Country/Region (2018-2023)
Table 31. Global Hepatic Encephalopathy Treatment Revenue by Country/Region (2018-2023) & ($ millions)
Table 32. Global Hepatic Encephalopathy Treatment Revenue Market Share by Country/Region (2018-2023)
Table 33. Americas Hepatic Encephalopathy Treatment Sales by Country (2018-2023) & (K Units)
Table 34. Americas Hepatic Encephalopathy Treatment Sales Market Share by Country (2018-2023)
Table 35. Americas Hepatic Encephalopathy Treatment Revenue by Country (2018-2023) & ($ Millions)
Table 36. Americas Hepatic Encephalopathy Treatment Revenue Market Share by Country (2018-2023)
Table 37. Americas Hepatic Encephalopathy Treatment Sales by Type (2018-2023) & (K Units)
Table 38. Americas Hepatic Encephalopathy Treatment Sales by Application (2018-2023) & (K Units)
Table 39. APAC Hepatic Encephalopathy Treatment Sales by Region (2018-2023) & (K Units)
Table 40. APAC Hepatic Encephalopathy Treatment Sales Market Share by Region (2018-2023)
Table 41. APAC Hepatic Encephalopathy Treatment Revenue by Region (2018-2023) & ($ Millions)
Table 42. APAC Hepatic Encephalopathy Treatment Revenue Market Share by Region (2018-2023)
Table 43. APAC Hepatic Encephalopathy Treatment Sales by Route (2018-2023) & (K Units)
Table 44. APAC Hepatic Encephalopathy Treatment Sales by Application (2018-2023) & (K Units)
Table 45. Europe Hepatic Encephalopathy Treatment Sales by Country (2018-2023) & (K Units)
Table 46. Europe Hepatic Encephalopathy Treatment Sales Market Share by Country (2018-2023)
Table 47. Europe Hepatic Encephalopathy Treatment Revenue by Country (2018-2023) & ($ Millions)
Table 48. Europe Hepatic Encephalopathy Treatment Revenue Market Share by Country (2018-2023)
Table 49. Europe Hepatic Encephalopathy Treatment Sales by Type (2018-2023) & (K Units)
Table 50. Europe Hepatic Encephalopathy Treatment Sales by Application (2018-2023) & (K Units)
Table 51. Middle East & Africa Hepatic Encephalopathy Treatment Sales by Country (2018-2023) & (K Units)
Table 52. Middle East & Africa Hepatic Encephalopathy Treatment Sales Market Share by Country (2018-2023)
Table 53. Middle East & Africa Hepatic Encephalopathy Treatment Revenue by Country (2018-2023) & ($ Millions)
Table 54. Middle East & Africa Hepatic Encephalopathy Treatment Revenue Market Share by Country (2018-2023)
Table 55. Middle East & Africa Hepatic Encephalopathy Treatment Sales by Route (2018-2023) & (K Units)
Table 56. Middle East & Africa Hepatic Encephalopathy Treatment Sales by Application (2018-2023) & (K Units)
Table 57. Key Market Drivers & Growth Opportunities of Hepatic Encephalopathy Treatment
Table 58. Key Market Challenges & Risks of Hepatic Encephalopathy Treatment
Table 59. Key Industry Trends of Hepatic Encephalopathy Treatment
Table 60. Hepatic Encephalopathy Treatment Raw Material
Table 61. Key Suppliers of Raw Materials
Table 62. Hepatic Encephalopathy Treatment Distributors List
Table 63. Hepatic Encephalopathy Treatment Customer List
Table 64. Global Hepatic Encephalopathy Treatment Sales Forecast by Region (2024-2029) & (K Units)
Table 65. Global Hepatic Encephalopathy Treatment Revenue Forecast by Region (2024-2029) & ($ millions)
Table 66. Americas Hepatic Encephalopathy Treatment Sales Forecast by Country (2024-2029) & (K Units)
Table 67. Americas Hepatic Encephalopathy Treatment Revenue Forecast by Country (2024-2029) & ($ millions)
Table 68. APAC Hepatic Encephalopathy Treatment Sales Forecast by Region (2024-2029) & (K Units)
Table 69. APAC Hepatic Encephalopathy Treatment Revenue Forecast by Region (2024-2029) & ($ millions)
Table 70. Europe Hepatic Encephalopathy Treatment Sales Forecast by Country (2024-2029) & (K Units)
Table 71. Europe Hepatic Encephalopathy Treatment Revenue Forecast by Country (2024-2029) & ($ millions)
Table 72. Middle East & Africa Hepatic Encephalopathy Treatment Sales Forecast by Country (2024-2029) & (K Units)
Table 73. Middle East & Africa Hepatic Encephalopathy Treatment Revenue Forecast by Country (2024-2029) & ($ millions)
Table 74. Global Hepatic Encephalopathy Treatment Sales Forecast by Route (2024-2029) & (K Units)
Table 75. Global Hepatic Encephalopathy Treatment Revenue Forecast by Route (2024-2029) & ($ Millions)
Table 76. Global Hepatic Encephalopathy Treatment Sales Forecast by Application (2024-2029) & (K Units)
Table 77. Global Hepatic Encephalopathy Treatment Revenue Forecast by Application (2024-2029) & ($ Millions)
Table 78. Mallinckrodt Pharmaceuticals Basic Information, Hepatic Encephalopathy Treatment Manufacturing Base, Sales Area and Its Competitors
Table 79. Mallinckrodt Pharmaceuticals Hepatic Encephalopathy Treatment Product Portfolios and Specifications
Table 80. Mallinckrodt Pharmaceuticals Hepatic Encephalopathy Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 81. Mallinckrodt Pharmaceuticals Main Business
Table 82. Mallinckrodt Pharmaceuticals Latest Developments
Table 83. Salix Pharmaceuticals Basic Information, Hepatic Encephalopathy Treatment Manufacturing Base, Sales Area and Its Competitors
Table 84. Salix Pharmaceuticals Hepatic Encephalopathy Treatment Product Portfolios and Specifications
Table 85. Salix Pharmaceuticals Hepatic Encephalopathy Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 86. Salix Pharmaceuticals Main Business
Table 87. Salix Pharmaceuticals Latest Developments
Table 88. GlaxoSmithKline plc. Basic Information, Hepatic Encephalopathy Treatment Manufacturing Base, Sales Area and Its Competitors
Table 89. GlaxoSmithKline plc. Hepatic Encephalopathy Treatment Product Portfolios and Specifications
Table 90. GlaxoSmithKline plc. Hepatic Encephalopathy Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 91. GlaxoSmithKline plc. Main Business
Table 92. GlaxoSmithKline plc. Latest Developments
Table 93. Pfizer Inc. Basic Information, Hepatic Encephalopathy Treatment Manufacturing Base, Sales Area and Its Competitors
Table 94. Pfizer Inc. Hepatic Encephalopathy Treatment Product Portfolios and Specifications
Table 95. Pfizer Inc. Hepatic Encephalopathy Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 96. Pfizer Inc. Main Business
Table 97. Pfizer Inc. Latest Developments
Table 98. ASKA Pharmaceutical Co., Ltd. Basic Information, Hepatic Encephalopathy Treatment Manufacturing Base, Sales Area and Its Competitors
Table 99. ASKA Pharmaceutical Co., Ltd. Hepatic Encephalopathy Treatment Product Portfolios and Specifications
Table 100. ASKA Pharmaceutical Co., Ltd. Hepatic Encephalopathy Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 101. ASKA Pharmaceutical Co., Ltd. Main Business
Table 102. ASKA Pharmaceutical Co., Ltd. Latest Developments
Table 103. Bausch Health Basic Information, Hepatic Encephalopathy Treatment Manufacturing Base, Sales Area and Its Competitors
Table 104. Bausch Health Hepatic Encephalopathy Treatment Product Portfolios and Specifications
Table 105. Bausch Health Hepatic Encephalopathy Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 106. Bausch Health Main Business
Table 107. Bausch Health Latest Developments
Table 108. Johnson & Johnson Services, Inc. Basic Information, Hepatic Encephalopathy Treatment Manufacturing Base, Sales Area and Its Competitors
Table 109. Johnson & Johnson Services, Inc. Hepatic Encephalopathy Treatment Product Portfolios and Specifications
Table 110. Johnson & Johnson Services, Inc. Hepatic Encephalopathy Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 111. Johnson & Johnson Services, Inc. Main Business
Table 112. Johnson & Johnson Services, Inc. Latest Developments
Table 113. Janssen Global Services Basic Information, Hepatic Encephalopathy Treatment Manufacturing Base, Sales Area and Its Competitors
Table 114. Janssen Global Services Hepatic Encephalopathy Treatment Product Portfolios and Specifications
Table 115. Janssen Global Services Hepatic Encephalopathy Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 116. Janssen Global Services Main Business
Table 117. Janssen Global Services Latest Developments
Table 118. Takeda Pharmaceutical Company Limited Basic Information, Hepatic Encephalopathy Treatment Manufacturing Base, Sales Area and Its Competitors
Table 119. Takeda Pharmaceutical Company Limited Hepatic Encephalopathy Treatment Product Portfolios and Specifications
Table 120. Takeda Pharmaceutical Company Limited Hepatic Encephalopathy Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 121. Takeda Pharmaceutical Company Limited Main Business
Table 122. Takeda Pharmaceutical Company Limited Latest Developments
Table 123. Merck & Co., Inc. Basic Information, Hepatic Encephalopathy Treatment Manufacturing Base, Sales Area and Its Competitors
Table 124. Merck & Co., Inc. Hepatic Encephalopathy Treatment Product Portfolios and Specifications
Table 125. Merck & Co., Inc. Hepatic Encephalopathy Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 126. Merck & Co., Inc. Main Business
Table 127. Merck & Co., Inc. Latest Developments
List of Figures
Figure 1. Picture of Hepatic Encephalopathy Treatment
Figure 2. Hepatic Encephalopathy Treatment Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Hepatic Encephalopathy Treatment Sales Growth Rate 2018-2029 (K Units)
Figure 7. Global Hepatic Encephalopathy Treatment Revenue Growth Rate 2018-2029 ($ Millions)
Figure 8. Hepatic Encephalopathy Treatment Sales by Region (2018, 2022 & 2029) & ($ Millions)
Figure 9. Product Picture of Oral
Figure 10. Product Picture of Injectable
Figure 11. Global Hepatic Encephalopathy Treatment Sales Market Share by Route in 2022
Figure 12. Global Hepatic Encephalopathy Treatment Revenue Market Share by Route (2018-2023)
Figure 13. Hepatic Encephalopathy Treatment Consumed in Hospital Pharmacy
Figure 14. Global Hepatic Encephalopathy Treatment Market: Hospital Pharmacy (2018-2023) & (K Units)
Figure 15. Hepatic Encephalopathy Treatment Consumed in Retail Pharmacy
Figure 16. Global Hepatic Encephalopathy Treatment Market: Retail Pharmacy (2018-2023) & (K Units)
Figure 17. Hepatic Encephalopathy Treatment Consumed in Online Pharmacy
Figure 18. Global Hepatic Encephalopathy Treatment Market: Online Pharmacy (2018-2023) & (K Units)
Figure 19. Global Hepatic Encephalopathy Treatment Sales Market Share by Application (2022)
Figure 20. Global Hepatic Encephalopathy Treatment Revenue Market Share by Application in 2022
Figure 21. Hepatic Encephalopathy Treatment Sales Market by Company in 2022 (K Units)
Figure 22. Global Hepatic Encephalopathy Treatment Sales Market Share by Company in 2022
Figure 23. Hepatic Encephalopathy Treatment Revenue Market by Company in 2022 ($ Million)
Figure 24. Global Hepatic Encephalopathy Treatment Revenue Market Share by Company in 2022
Figure 25. Global Hepatic Encephalopathy Treatment Sales Market Share by Geographic Region (2018-2023)
Figure 26. Global Hepatic Encephalopathy Treatment Revenue Market Share by Geographic Region in 2022
Figure 27. Americas Hepatic Encephalopathy Treatment Sales 2018-2023 (K Units)
Figure 28. Americas Hepatic Encephalopathy Treatment Revenue 2018-2023 ($ Millions)
Figure 29. APAC Hepatic Encephalopathy Treatment Sales 2018-2023 (K Units)
Figure 30. APAC Hepatic Encephalopathy Treatment Revenue 2018-2023 ($ Millions)
Figure 31. Europe Hepatic Encephalopathy Treatment Sales 2018-2023 (K Units)
Figure 32. Europe Hepatic Encephalopathy Treatment Revenue 2018-2023 ($ Millions)
Figure 33. Middle East & Africa Hepatic Encephalopathy Treatment Sales 2018-2023 (K Units)
Figure 34. Middle East & Africa Hepatic Encephalopathy Treatment Revenue 2018-2023 ($ Millions)
Figure 35. Americas Hepatic Encephalopathy Treatment Sales Market Share by Country in 2022
Figure 36. Americas Hepatic Encephalopathy Treatment Revenue Market Share by Country in 2022
Figure 37. Americas Hepatic Encephalopathy Treatment Sales Market Share by Route (2018-2023)
Figure 38. Americas Hepatic Encephalopathy Treatment Sales Market Share by Application (2018-2023)
Figure 39. United States Hepatic Encephalopathy Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 40. Canada Hepatic Encephalopathy Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 41. Mexico Hepatic Encephalopathy Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 42. Brazil Hepatic Encephalopathy Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 43. APAC Hepatic Encephalopathy Treatment Sales Market Share by Region in 2022
Figure 44. APAC Hepatic Encephalopathy Treatment Revenue Market Share by Regions in 2022
Figure 45. APAC Hepatic Encephalopathy Treatment Sales Market Share by Route (2018-2023)
Figure 46. APAC Hepatic Encephalopathy Treatment Sales Market Share by Application (2018-2023)
Figure 47. China Hepatic Encephalopathy Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 48. Japan Hepatic Encephalopathy Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 49. South Korea Hepatic Encephalopathy Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 50. Southeast Asia Hepatic Encephalopathy Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 51. India Hepatic Encephalopathy Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 52. Australia Hepatic Encephalopathy Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 53. China Taiwan Hepatic Encephalopathy Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 54. Europe Hepatic Encephalopathy Treatment Sales Market Share by Country in 2022
Figure 55. Europe Hepatic Encephalopathy Treatment Revenue Market Share by Country in 2022
Figure 56. Europe Hepatic Encephalopathy Treatment Sales Market Share by Route (2018-2023)
Figure 57. Europe Hepatic Encephalopathy Treatment Sales Market Share by Application (2018-2023)
Figure 58. Germany Hepatic Encephalopathy Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 59. France Hepatic Encephalopathy Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 60. UK Hepatic Encephalopathy Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 61. Italy Hepatic Encephalopathy Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 62. Russia Hepatic Encephalopathy Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 63. Middle East & Africa Hepatic Encephalopathy Treatment Sales Market Share by Country in 2022
Figure 64. Middle East & Africa Hepatic Encephalopathy Treatment Revenue Market Share by Country in 2022
Figure 65. Middle East & Africa Hepatic Encephalopathy Treatment Sales Market Share by Route (2018-2023)
Figure 66. Middle East & Africa Hepatic Encephalopathy Treatment Sales Market Share by Application (2018-2023)
Figure 67. Egypt Hepatic Encephalopathy Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 68. South Africa Hepatic Encephalopathy Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 69. Israel Hepatic Encephalopathy Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 70. Turkey Hepatic Encephalopathy Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 71. GCC Country Hepatic Encephalopathy Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 72. Manufacturing Cost Structure Analysis of Hepatic Encephalopathy Treatment in 2022
Figure 73. Manufacturing Process Analysis of Hepatic Encephalopathy Treatment
Figure 74. Industry Chain Structure of Hepatic Encephalopathy Treatment
Figure 75. Channels of Distribution
Figure 76. Global Hepatic Encephalopathy Treatment Sales Market Forecast by Region (2024-2029)
Figure 77. Global Hepatic Encephalopathy Treatment Revenue Market Share Forecast by Region (2024-2029)
Figure 78. Global Hepatic Encephalopathy Treatment Sales Market Share Forecast by Route (2024-2029)
Figure 79. Global Hepatic Encephalopathy Treatment Revenue Market Share Forecast by Route (2024-2029)
Figure 80. Global Hepatic Encephalopathy Treatment Sales Market Share Forecast by Application (2024-2029)
Figure 81. Global Hepatic Encephalopathy Treatment Revenue Market Share Forecast by Application (2024-2029)

※参考情報 肝性脳症は、肝臓の機能不全に伴う神経精神的障害として定義されます。この状態は、肝臓が適切に毒素を除去できないことに起因し、特にアンモニアの蓄積が脳に悪影響を与えることが主な要因とされています。肝性脳症の症状は、軽度の精神的混乱から昏睡に至るまで多岐にわたり、患者の生活の質を著しく低下させる可能性があります。 肝性脳症の特徴は多様で、まずはその臨床症状に目を向ける必要があります。初期段階では、不眠、集中力の低下、頭痛などの軽い神経症状が見られることが多いです。これが進行するにつれて、意識障害、徘徊、性格の変化、さらには幻覚や昏睡状態に至ることもあります。特に、アニマルスコア（かんすたん度）という評価スケールが用いられることがあり、肝性脳症の重症度を定量的に評価する手段として広く用いられています。 肝性脳症には主に二つのタイプがあります。一つは、肝疾患が急性に進行することで生じる「急性肝性脳症」です。これは急性肝炎や肝不全などの急性の状況で見られることが多く、緊急の治療が必要です。もう一つは「慢性肝性脳症」で、肝硬変などの慢性疾患に伴い、徐々に症状が進行するものです。慢性の場合は、責任となる病態が慢性的に継続するため、治療アプローチも長期的な管理が求められます。 治療の目的は、肝性脳症の症状を軽減し、再発を防ぐことにあります。治療方法は多岐にわたり、まず基本的なアプローチとして必要な栄養管理が挙げられます。特に、たんぱく質の摂取量を適切に管理することが求められます。過度なたんぱく質摂取はアンモニアの生成を促進するため、適度な制限が推奨されます。 一方、薬物治療も重要な役割を果たします。最も広く用いられているのが、ラクトロースという薬剤であり、腸内でのアンモニアの吸収を減少させる効果があります。この薬剤は、大腸内のpHを変化させることによって、アンモニアをより無害な形態に変換し、排泄を促進します。また、抗生物質（例：リファキシミン）も使用されることがあり、腸内の有害な細菌の増殖を抑えることによって、アンモニアの産生を減少させます。 さらに、肝性脳症の管理には、合併症への対応も含まれます。たとえば、肝不全の場合は肝移植が有効な治療手段となることがあります。肝移植は、根本的な問題を解決する手段として期待されていますが、適応やタイミングは個々の患者によって異なるため、慎重な判断が求められます。 関連技術としては、肝性脳症の診断およびモニタリングに向けた新しい biomarkers（バイオマーカー）の研究が進行しています。これにより、より早期に肝性脳症を発見し、適切な治療を行うための手段が検討されています。特に、血液中の特定の物質（例：血中アンモニア濃度など）の定量化が、診断精度や治療効果のモニタリングに役立つと考えられています。 また、現在の研究は、肝性脳症の病態生理を深く理解することに焦点を当てています。脳内の神経伝達物質の変化や、細胞障害のメカニズムを解明することで、より効果的な新薬の開発が期待されています。 総じて言えることは、肝性脳症は複雑な病態であり、多様な治療アプローチが必要となる病気です。患者の状態や背景に応じた個別的なアプローチが求められ、今後の研究の進展によってさらなる治療の選択肢が増えることが期待されています。肝性脳症の治療は、医療従事者の適切な判断と患者の協力によって最適な結果を得られることが目指されるべきです。患者の生活の質向上を実現するために、専門的な知識と経験が必要不可欠です。

❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer